

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. <b>P51365</b>	SERIAL NO. <b>10/518,654</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use several sheets if necessary)</i>		APPLICANT Brook et al.	
		FILING DATE <b>16 December 2004</b>	GROUP <b>1626</b>

## U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

## FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AF		New Drug Application (NDA) for Coreg CR (carvedilol phosphate) Extended Release Capsules, NDA 22-012 Excerpt, Section m3.2.S.4.5, Justification of Specification, submitted 21 December 2005, Approved 20 October 2006, pp 3-5.
AF		Chemical & Engineering News, February 24, 2003, pp. 32-35.
AF		Jain et al., "Polymorphism in Pharmacy", Indian Drugs, 23 (6), 1986, pp. 315 -329.
EXAMINER /Andrew Freistein/ (03/07/2007)		DATE CONSIDERED 03/07/2007
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		